Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty

NCT04785625 is registered in ClinicalTrials.gov with Innocoll as lead sponsor.

NCT NCT04785625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04785625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty
Lead sponsor
Innocoll
Phase
Phase 3
Overall status
Completed
Start date
April 29, 2021
Completion date
October 27, 2021
Enrollment
366 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

abdominoplasty, pain, postoperative